3,747 IDEXX Laboratories, Inc. $IDXX Shares Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 23.3% during the 3rd quarter, Holdings Channel reports. The fund owned 19,848 shares of the company’s stock after buying an additional 3,747 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in IDEXX Laboratories were worth $10,363,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IDXX. Bank of New York Mellon Corp acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $628,223,000. Arrowstreet Capital Limited Partnership increased its position in IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares during the last quarter. International Assets Investment Management LLC increased its position in IDEXX Laboratories by 30,484.1% during the third quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock worth $122,336,000 after purchasing an additional 233,508 shares during the last quarter. Alyeska Investment Group L.P. raised its stake in IDEXX Laboratories by 97.3% during the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after purchasing an additional 197,808 shares during the period. Finally, American Capital Management Inc. purchased a new position in IDEXX Laboratories during the second quarter worth about $85,341,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 1.5%

Shares of NASDAQ:IDXX opened at $690.24 on Wednesday. The company has a market capitalization of $54.38 billion, a price-to-earnings ratio of 46.54 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The business has a 50-day moving average price of $569.11 and a 200 day moving average price of $573.65. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. IDEXX Laboratories’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.22 earnings per share. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They set a “buy” rating on the stock. Morgan Stanley upped their price objective on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Seven analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

Read Our Latest Research Report on IDXX

Insiders Place Their Bets

In other news, Director Daniel M. Junius sold 1,200 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the sale, the director directly owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. The trade was a 33.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Lane sold 3,979 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $688.64, for a total value of $2,740,098.56. Following the completion of the transaction, the executive vice president directly owned 4,076 shares of the company’s stock, valued at $2,806,896.64. This trade represents a 49.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 41,428 shares of company stock valued at $28,567,934. 0.79% of the stock is owned by company insiders.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Further Reading

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.